Purpose: We evaluated whether initial diagnostic parameters could predict the confirmatory biopsy result in patients initiating active surveillance for prostate cancer, to determine whether some men at low risk for disease reclassification could be spared unnecessary biopsy. Materials and Methods: The cohort included 392 men with Gleason 6 prostate cancer on initial biopsy undergoing confirmatory biopsy. We used univariate and multivariable logistic regression to assess if high grade cancer (Gleason 7 or greater) on confirmatory biopsy could be predicted from initial diagnostic parameters (prostate specific antigen density, magnetic resonance imaging result, percent positive cores, percent cancer in positive cores and total tumor length). Results: Median patient age was 62 years (IQR 56e66) and 47% of patients had a dominant or focal lesion on magnetic resonance imaging. Of the 392 patients 44 (11%) had high grade cancer on confirmatory biopsy, of whom 39 had Gleason 3þ4, 1 had 4þ3, 3 had Gleason 8 and 1 had Gleason 9 disease. All predictors were significantly associated with high grade cancer at confirmatory biopsy on univariate analysis. However, in the multivariable model only prostate specific antigen density and total tumor length were significantly associated (AUC 0.85). Using this model to select patients for confirmatory biopsy would generally provide a higher net benefit than performing confirmatory biopsy in all patients, across a wide range of threshold probabilities. Conclusions: If externally validated, a model based on initial diagnostic criteria could be used to avoid confirmatory biopsy in many patients initiating active surveillance.
CURRENT protocols for monitoring men on AS involve repeat digital rectal examination, PSA and repeat prostate biopsy.
1e3 Given that systematic biopsy may miss Gleason pattern 4 disease, 4e7 confirmatory biopsy has become a mainstay of AS. However, there are several reasons why avoiding repeat biopsy would be desirable.
Prostate biopsy is an invasive procedure, is sometimes poorly tolerated, and is commonly associated with hematospermia, hematuria and transient worsening of lower urinary tract symptoms.
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† Financial interest and/or other relationship with Opko. increased in recent years as a result of emerging antimicrobial resistance. 8 The risk of infectious complications increases with each additional biopsy. 9 Using clinical and tumor characteristics, attempts have been made to identify those patients at risk for biopsy progression. Men with a higher PSA density, 10, 11 positive confirmatory biopsies 10 and a higher number of positive cores 11 have been shown to carry an increased risk of progression on AS. We sought to determine whether clinical predictors of progression, including imaging in the form of MRI, could predict the results of the confirmatory biopsy with sufficient accuracy to allow some patients to avoid biopsy.
MATERIALS AND METHODS

Patient Population
A review of our institutional database identified 583 patients on AS from December 2007 to December 2013 who underwent MRI and a confirmatory biopsy. These patients came from across the United States, consistent with our role as a dedicated cancer hospital. Inclusion criteria for AS at our institution are clinical stage T2a or less, Gleason score 3þ3¼6 or less, PSA 10 ng/ml or less, and 3 or fewer positive cores with 50% or less positivity in a single core. To maintain consistency with these criteria we excluded 3 patients who chose AS despite an initial biopsy score of 4þ3, 31 patients with Gleason 3þ4 and 35 with a baseline PSA greater than 10 ng/ml. We also excluded 5 patients missing baseline PSA and 93 missing complete initial biopsy information. Three patients were excluded for whom more than 14 months had elapsed between the diagnostic and confirmatory biopsy. Lastly, we excluded 22 patients who underwent MRI after confirmatory biopsy and 4 who underwent MRI more than 1 year before confirmatory biopsy. This left a final cohort of 392 patients.
MRI Protocol and Analysis
We used whole body MRI units (GE Healthcare, Waukesha, Wisconsin) at 1.5T (62 patients) and 3T (305 patients). An endorectal coil was used in 370 cases. Data on MRI acquisition parameters were not available for 25 patients. MRI parameters varied with time as clinical protocols at our institution evolved with new developments. Twenty studies involved anatomical T2WI alone. Of the multiparametric MRI studies 281 used DWI and dynamic contrast enhanced imaging in addition to T2WI. DWI and T2WI were used in 75 cases, dynamic contrast enhanced imaging and T2WI in 11 cases, and the combination of DWI, T2WI and magnetic resonance spectroscopy in 6 cases. A total of 29 MRI studies were performed elsewhere. MRIs reporting a dominant prostatic lesion were considered positive studies for this project. We defined a dominant lesion on MRI as a nodule demonstrating reduced signal intensity on T2WI, restricted diffusion on DWI and/or early enhancement or rapid washout compared to adjacent prostate tissue on dynamic contrast enhanced imaging. In cases for which these sequences were unavailable, MRI positivity was determined as a score greater than 3 on a Likert-type scale. Similar to the PI-RADS (Prostate Imaging Reporting and Data System) score, this corresponds to a greater than 50% likelihood of prostate cancer.
Biopsy Protocol
All patients underwent systematic peripheral and transition zone sampling under local anesthesia at the time of confirmatory biopsy. In those cases in which the surgeon used MRI to help target confirmatory biopsies, such targeting was cognitive. MR fusion guidance systems were not used in this cohort.
Statistical Analysis
We assessed whether initial diagnostic parameters could predict confirmatory biopsy results. Thus, we used univariate and multivariable logistic regression to determine whether any grade of prostate cancer and high grade prostate cancer (Gleason 7 or greater) on confirmatory biopsy could be predicted from PSA density (initial PSA in ng/ml divided by MRI prostate volume in cm 3 ), MRI results (presence/absence of dominant lesion) and initial biopsy results (percent positive cores out of all cores, percent cancer in all positive cores and total tumor length from all positive cores). If 2 areas in the same core contained cancer, then the length of each segment was added, with the exclusion of intervening normal tissue. Biopsy parameters were analyzed as continuous variables. The area under the receiver operating curve was used to assess the discrimination of the model. We also performed decision curve analysis for the outcome of high grade cancer to assess whether our model would be clinically useful in deciding whether to perform confirmatory biopsy. 12 We used tenfold cross-validation to address overfit. The decision curve was assessed up to a threshold probability of 15%, as this was viewed as the highest threshold risk of high grade cancer for which a physician would forgo a confirmatory biopsy. All statistical analyses were conducted using StataÒ 13.0. 
RESULTS
Patient characteristics are shown in table 1. Median patient age was 62 years (IQR 56e66) and almost half had a positive MRI (47%). There were 44 patients (11%) with high grade cancer on confirmatory biopsy, although only 4 (1%) had a grade higher than 4þ3. Confirmatory biopsies were performed at a median of 5 months after the initial biopsy and MRIs were done at a median of 3 months after the initial biopsy. On univariate analysis all predictors except positive MRI were significantly associated with any grade of cancer at confirmatory biopsy (table 2) . In the multivariable model only percent positive cores and percent cancer from all positive cores were significantly associated with the outcome of any cancer found on confirmatory biopsy. This model had a tenfold cross-validated AUC of 0.72. In contrast, on univariate analysis MRI positivity was significantly associated with the presence of high grade (Gleason 7 or greater) cancer on confirmatory biopsy (table 3) . However, in the multivariable model only total tumor length and PSA density had a significant association with high grade cancer on confirmatory biopsy. This model had a tenfold cross-validated AUC of 0.85.
Although only total tumor length and PSA density were significant, we evaluated the performance of the full prespecified multivariable model for high grade cancer using the MRI result, PSA density, percent positive cores, total tumor length and percent cancer. We used decision curve analysis on the tenfold cross-validated predicted risks from this multivariable model (see figure) . Evaluating the decision curve up to a threshold probability of 15%, we found that using our model to determine which patients undergo a confirmatory biopsy would generally provide a higher net benefit than performing confirmatory biopsy in all patients.
The model only ceased being beneficial if a urologist was willing to order a confirmatory biopsy for men with a risk of high grade disease of 1% or 2%, that is, he or she would be willing to conduct 50 to 100 confirmatory biopsies to find 1 case of upgrading. As an illustration of the clinical effects of using the model, if we only wished to perform confirmatory biopsy in patients with a risk of high grade cancer of 10% or greater, the model would indicate confirmatory biopsies in 240 of 1,000 patients, reducing the number of confirmatory biopsies by more than 75% (table 4). We would find 89 (37%) high grade cancers among these 240 patients, while 23 (3%) of the 760 patients who were not indicated for a confirmatory biopsy would be harboring high grade disease. Of these 23 patients 20 would have 3þ4 Gleason on confirmatory biopsy and 3 would have Gleason 4þ4 on confirmatory biopsy.
DISCUSSION
In the present study 11% of patients meeting the initial criteria for AS had high grade cancer on confirmatory biopsy. We showed that using our model to select patients for confirmatory biopsy would generally provide a higher net benefit than performing confirmatory biopsy in all patients, across a wide range of threshold probabilities. For physicians unwilling to accept even a 5% risk of missing Gleason 7 or greater disease, our model is still able to avoid confirmatory biopsy for more than half of the patient population. Along with total tumor length, we found that PSA density was significantly associated with Gleason 7 or greater cancer at confirmatory biopsy in our multivariable model. In a recent update on the PRIAS (Prostate Cancer Research International Active Surveillance) study Bul et al identified PSA density and the number of positive cores as the strongest predictors of reclassification on confirmatory biopsy.
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Likewise Cary et al identified an association between lower PSA density and decreased odds of biopsy progression at 3 years in a cohort of 465 patients. 10 San Francisco et al found PSA density greater than 0.08 ng/ml/cm 3 and positive family history as significant predictors of progression in a cohort of 135 patients undergoing saturation confirmatory biopsy. 13 In another small study PSA density greater than 0.15 ng/ml/cm 3 was associated with upgrading in 31% of patients undergoing repeat biopsy vs only 10% in patients with a PSA density less than 0.15 ng/ml/cm 3 .
14 Although a previous study from our institution did not associate PSA density with biopsy progression, 4 it should be noted that this finding was based on PSA density at confirmatory biopsy rather than at diagnosis as in the present analysis.
In a cohort of 273 men Wang et al recently tested the ability of several nomograms, 15 such as those of Kattan, 16 Steyerberg, 17 Nakanishi 18 and Chun 19 et al, to predict indolent disease. These men met Epstein criteria for indolent disease and underwent multiple biopsies and/or delayed radical prostatectomy during a minimum 6-month period. Unsurprisingly patients with progression had lower probabilities of indolent disease than those without. 15 The Nakanishi nomogram, the only one to include PSA density as a predictor, had the best performance with an AUC of 0.67 for biopsy progression.
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The authors also performed decision curve analysis, and determined that these nomograms only provided a net benefit when the threshold probability of progression was between 40% and 60%. Since the norm is to offer confirmatory biopsy to everyone, and no one would withhold confirmatory biopsy until a patient had a 40% chance of nonindolent cancer, the real clinical threshold is obviously lower than 40%. Our model, which incorporates PSA density, MRI results and initial biopsy results, delivers a reasonable estimation of Decision curve for predicting high grade cancer on confirmatory biopsy. Dashed line is net benefit of providing confirmatory biopsy based on PSA density, MRI results, percent positive cores, total tumor length and percent cancer. Black line is net benefit of providing all patients with confirmatory biopsy. Gray line is net benefit of providing no patients with confirmatory biopsy. Curve shows that net benefit of using model to choose who undergoes confirmatory biopsy exceeds benefit of performing confirmatory biopsy, except for urologists with extremely low threshold probabilities of less than 2%. A Likert-type scale was only used for part of the study period (2009 onward) and before this time the presence of a dominant or focal lesion on MRI was interpreted from the review of radiology reports. However, when we performed a sensitivity analysis using Likert scores in the multivariable model, our results were unchanged. On multivariable analysis only PSA density (OR 1.99 per 1 ng/ml/10 cm 3 , p ¼ 0.032) and total tumor length (OR 1.37 per mm, p ¼ 0.002) were significantly associated with high grade cancer on confirmatory biopsy. We also allowed MRIs performed up to 12 months before confirmatory biopsy, whereas the prior study only included MRIs and biopsies performed within 6 months of diagnosis. Thus, we performed a sensitivity analysis excluding 7 patients who underwent MRI before 2009 and 44 patients whose MRI was more than 6 months before the confirmatory biopsy. The result was essentially similar. PSA density (OR 2.7 per 1 ng/ml/ 10 cm 3 , p ¼ 0.002) and total tumor length (OR 1.4 per mm, p <0.001) achieved significance in this model, whereas positive MRI did not (OR 1.03, p ¼ 0.9).
We also performed a sensitivity analysis including only those 281 patients who underwent multiparametric MRI with the combination of T2WI, DWI and dynamic contrast enhanced imaging. Once again, the results were not importantly changed. PSA density (OR 2.52 per 1 ng/ml/10 cm 3 , p ¼ 0.009) and total tumor length (OR 1.43 per mm, p ¼ 0.0003) were the only factors on initial diagnosis that were significantly associated with high grade cancer at confirmatory biopsy in the multivariable model. A validation study using a prospective cohort with standardized MRI acquisition and reporting protocols may help clarify whether MRI has a predictive role in the context of our multivariable model. While our multivariable analysis did not demonstrate MRI to be predictive of results on confirmatory biopsy, MRI may still be useful in this population as a baseline study and as a guide for targeted biopsy. Hu et al found that 36.3% of men undergoing multiparametric MRI ultrasound fusion confirmatory biopsy had disease reclassified beyond Epstein criteria. 21 In contrast, Vasarainen et al did not find a correlation between MRI positivity and subsequent biopsy findings, or discontinuation of AS, in 80 patients enrolled in the Finnish arm of PRIAS, despite identifying an anatomical lesion suggestive of cancer in 50%. 26 Taken together, this variability suggests that MRI in isolation may not adequately predict the risk of cancer upgrading on subsequent biopsy.
The primary limitation of our study is that our model requires external validation. It was built on retrospective data from a single National Cancer Institute designated cancer center, meaning that it may not be representative of the overall patient population and may be optimistic despite tenfold cross-validation. Calibration may also differ between cohorts. We may have failed to see a strong effect of MRI because systematic rather than MR assisted biopsy was used. Future research might involve testing the model in a cohort of patients undergoing MR fusion biopsy. If the model stands up to external validation, it should be refined and made available as a nomogram for day-to-day clinical use.
CONCLUSIONS
We proposed a model based on initial diagnostic criteria that could be used to determine the need for confirmatory biopsy in patients initiating AS. The model shows considerable promise, with the potential to avoid many additional biopsies while still detecting the majority of high grade cancers. Should it withstand external validation, this model would become a valuable tool in the treatment of patients on active surveillance.
